Cyclerion Therapeutics, Inc.

Cyclerion Therapeutics is a U.S.-based biopharmaceutical company focused on building a new pipeline for neuropsychiatric diseases. After divesting legacy assets, it is now centered on developing an individualized therapy for treatment-resistant depression and selectively monetizing remaining soluble guanylate cyclase assets through licensing and option transactions.

−170,1 %

+3,7 %

5.15

5.15

— Cyclerion Therapeutics, Inc.
%
TRD pipeline development10% Development of an individualized therapy candidate for treatment-resistant depression.
Licensing and option revenue60% Upfront fees, extension fees, and reimbursements from licensing and option agreements.
Asset sales and development materials30% Sales of development materials and other transaction-based monetization of legacy assets.

Cyclerion’s direct customers are primarily pharmaceutical and biotech counterparties that license or option its assets,...

  • Pharmaceutical and biotech partnersprimary

    Buy or option legacy assets and development materials to advance their own pipelines or evaluate licensing rights.

  • Academic IP licensorssecondary

    Provide foundational intellectual property for the TRD program, enabling Cyclerion to build a new clinical asset.

  • Future prescribers and treatment centersemerging

    Would adopt the TRD therapy if approved, driving eventual commercial demand.

Cyclerion is headquartered in the United States and its reported transactions and cash management are U.S.-centric...

  • •Headquartered in the United States
  • •Reported revenue comes from U.S.-based partner transactions
  • •Cash is held in U.S. government money market funds
  • •Future TRD commercialization would likely start in the U.S.
  • •International exposure is currently limited

Cyclerion is repositioning itself around a single foundational TRD program while reducing operating expense and...

01
Advance the TRD programshort-term

A focused clinical asset can become the company’s core value driver and commercial foundation.

02
Monetize legacy assetsshort-term

Option and license transactions can generate non-dilutive cash while the new pipeline is built.

03
Strengthen financing capacityshort-term

The company needs external capital to fund operations and development.

Cyclerion remains a development-stage company with limited revenue, so its ability to continue operations depends on...

critical

Liquidity and going-concern risk

The company has minimal unrestricted cash and depends on capital markets and partner transactions to fund operations.

Scope
Operating runway and ability to continue development
Materiality
high
high

Clinical development failure

The TRD program is still in development and may not demonstrate safety, efficacy, or differentiation.

Scope
Core pipeline value
Materiality
high
high

Partner and asset monetization uncertainty

Revenue currently depends on option fees, reimbursements, and asset sales that may not recur.

Scope
Near-term revenue and cash generation
Materiality
high
medium

Dilution from equity financing

Funding needs may require issuing common stock or other securities.

Scope
Shareholder value and per-share economics
Materiality
medium
Revenue recognition for option and purchase agreements
Affects quarterly comparability and reported top-line volatility
R&D expense accruals
Can affect operating loss and prepaid/accrued balances
Capitalization of advance payments
Influences balance sheet assets and near-term expense recognition
Going-concern assessment
Important for solvency and disclosure risk

Voyager Therapeutics, Inc.

VYGR · Biological Products, (No Diagnostic Substances)

Gain Therapeutics, Inc.

GANX · Pharmaceutical Preparations

BICYCLE THERAPEUTICS PLC

BCYC · Pharmaceutical Preparations

Neuphoria Therapeutics Inc.

NEUP · Pharmaceutical Preparations

Silexion Therapeutics Corp

SLXN · Biological Products, (No Diagnostic Substances)

Serina Therapeutics, Inc.

SER · Pharmaceutical Preparations

: 28/04/2026